Skip to main
ALNY
ALNY logo

Alnylam Pharmaceuticals (ALNY) Stock Forecast & Price Target

Alnylam Pharmaceuticals (ALNY) Analyst Ratings

Based on 43 analyst ratings
Buy
Strong Buy 47%
Buy 30%
Hold 21%
Sell 2%
Strong Sell 0%

Bulls say

Alnylam Pharmaceuticals reported impressive total product revenue of $451 million for the fourth quarter, reflecting a 30% year-over-year increase, with full-year revenue rising by 33% to $1.65 billion. The company benefits from significant market potential, particularly in the ATTR-CM segment, where diagnosis rates have surged nearly tenfold since 2019, indicating a vast opportunity as approximately 80% of patients remain undiagnosed. Additionally, Alnylam's focus on innovative therapies in rare diseases and cardiovascular conditions, alongside strategic partnerships that enhance cash flow through upfront fees and potential royalties, supports a robust financial outlook.

Bears say

Alnylam Pharmaceuticals faces significant financial challenges, with substantial accumulated losses and an expected extended timeline before achieving profitability. The company’s reliance on future regulatory approvals for its therapeutic products presents a high-risk outlook, as any delays or failures could lead to downward revisions in financial projections and valuation metrics. Additionally, potential legal disputes related to intellectual property and increased competition may further hinder revenue growth and prolong the path to financial sustainability.

Alnylam Pharmaceuticals (ALNY) has been analyzed by 43 analysts, with a consensus rating of Buy. 47% of analysts recommend a Strong Buy, 30% recommend Buy, 21% suggest Holding, 2% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alnylam Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alnylam Pharmaceuticals (ALNY) Forecast

Analysts have given Alnylam Pharmaceuticals (ALNY) a Buy based on their latest research and market trends.

According to 43 analysts, Alnylam Pharmaceuticals (ALNY) has a Buy consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $300.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $300.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alnylam Pharmaceuticals (ALNY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.